Bank of New York Mellon Corp lifted its holdings in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 2.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 228,350 shares of the biotechnology company’s stock after purchasing an additional 4,474 shares during the quarter. Bank of New York Mellon Corp owned about 0.82% of Five Prime Therapeutics worth $6,876,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Creative Planning grew its position in shares of Five Prime Therapeutics by 0.8% in the 2nd quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 54 shares during the period. Rhumbline Advisers grew its position in shares of Five Prime Therapeutics by 1.4% in the 2nd quarter. Rhumbline Advisers now owns 34,282 shares of the biotechnology company’s stock valued at $1,032,000 after purchasing an additional 484 shares during the period. Trillium Asset Management LLC grew its position in shares of Five Prime Therapeutics by 1.5% in the 2nd quarter. Trillium Asset Management LLC now owns 65,295 shares of the biotechnology company’s stock valued at $1,966,000 after purchasing an additional 955 shares during the period. Bank of America Corp DE grew its position in shares of Five Prime Therapeutics by 5.8% in the 1st quarter. Bank of America Corp DE now owns 18,558 shares of the biotechnology company’s stock valued at $671,000 after purchasing an additional 1,025 shares during the period. Finally, American International Group Inc. grew its position in shares of Five Prime Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 16,614 shares of the biotechnology company’s stock valued at $601,000 after purchasing an additional 1,100 shares during the period. Institutional investors and hedge funds own 84.05% of the company’s stock.

FPRX has been the subject of several research analyst reports. Jefferies Group LLC reiterated a “buy” rating and issued a $55.00 price objective on shares of Five Prime Therapeutics in a research report on Thursday, June 8th. BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Royal Bank Of Canada initiated coverage on Five Prime Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $41.00 price objective for the company. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $39.00 price objective on shares of Five Prime Therapeutics in a research report on Friday, September 22nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $54.86.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) opened at 40.91 on Friday. Five Prime Therapeutics, Inc. has a 52-week low of $25.97 and a 52-week high of $60.98. The firm’s 50-day moving average price is $31.18 and its 200-day moving average price is $32.04. The firm’s market cap is $1.14 billion.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.43). Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The firm had revenue of $7.80 million during the quarter, compared to analyst estimates of $8.32 million. During the same period last year, the business posted ($0.49) EPS. The company’s revenue was down 16.1% on a year-over-year basis. Equities research analysts expect that Five Prime Therapeutics, Inc. will post ($5.16) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/01/five-prime-therapeutics-inc-fprx-shares-bought-by-bank-of-new-york-mellon-corp.html.

Five Prime Therapeutics Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.